Spots Global Cancer Trial Database for Vorinostat and Palliative Radiotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Vorinostat and Palliative Radiotherapy
Official Title: Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
Study ID: NCT00455351
Interventions
Study Description
Brief Summary: Phase I study. Side-effects when combined with standard palliative radiotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Norwegian Radium Hospital, Oslo, , Norway
Contact Details
Name: Sigbjørn Smeland, MD,PhD
Affiliation: Norwegian Radium Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
